Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2025-03-17 Annual Report
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
Annual Report and Accounts 2024 (ESEF Version)
Annual Report Classification · 100% confidence The document contains detailed financial data for the fiscal year 2024, including net revenue, adjusted net income, operating profit, and cash and investments. It also includes a strategic report discussing the company's vision, market context, and operational highlights. The document is titled 'Annual Report and Accounts 2024' and covers a full fiscal year (2024-01-01 to 2024-12-31). The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial statements, strategic discussion, and forward-looking statements aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, so it is not classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2024
2025-03-17 English
Annual Report and Accounts 2024 (ESEF Version)
Annual Report Classification · 100% confidence The document is explicitly titled 'Indivior Annual Report and Accounts 2024'. It contains comprehensive sections including a Strategic Report, Financial Highlights, Financial Statements, Independent Auditors' Report, and Governance information. It covers the full fiscal year ending December 31, 2024, and provides detailed financial data, management commentary, and regulatory disclosures. It meets all criteria for an Annual Report. FY 2024
2025-03-17 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification filed via RNS (RNS Number : 9775A) concerning 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR')'. It details the vesting and delivery of shares for the CEO and CFO following a deferred bonus plan. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2025-03-17 English
Annual Financial Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2463 characters) released via RNS (London Stock Exchange news service). The primary purpose of the text is to announce that the '2024 Annual Report and Accounts' has been published on the company website and will be submitted to the FCA's National Storage Mechanism. It explicitly states the publication of the report rather than containing the full report content itself. According to Rule 2 ('MENU VS MEAL' Rule), a short document announcing the publication of a report should be classified as a Report Publication Announcement (RPA). It also mentions the AGM Notice, but the core action described is the publication announcement.
2025-03-17 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM'. It details a 'Conditional Award' granted to the Chief Executive Officer (Mark Crossley) under a deferred bonus plan. This type of filing, reporting personal share transactions by directors/executives, directly corresponds to the definition of Director's Dealing. The document explicitly mentions being provided by 'RNS, the news service of the London Stock Exchange', which is a regulatory announcement mechanism, but the specific content dictates the classification as DIRS over the general RNS fallback. The document length is short (3449 chars), but it is the primary disclosure itself, not an announcement of a separate report.
2025-03-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 7508A' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' detailing an acquisition of voting rights by Madison Avenue Partners LP, crossing a threshold (from 4.05% to 5.18%). This specific type of regulatory filing concerning changes in significant share ownership aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific and appropriate classification.
2025-03-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.